Unicycive Therapeutics review

The short version

Unicycive is a very small California company, worth around $100 million, with one main drug. Oxylanthanum carbonate (OLC) is a pill for people on dialysis whose kidneys can no longer remove phosphate from the blood. It relies on a known ingredient, so its science is not the issue. The issue is that the FDA has now rejected it twice because of a factory the company does not own.

The latest FDA decision: rejected

On 30 June 2026 the FDA rejected OLC for the second time, citing the same problems at the third-party manufacturer as in June 2025. It did not visit the factory during the review, raised no efficacy or safety concerns and asked for no further data (Unicycive Q2 2026 update). The shares fell about 31% from the close before the news to the close after it, as our FDA Decision Calendar shows.

What it makes

Kidneys normally remove phosphate. On dialysis it builds up in the blood, which damages bones and blood vessels, so most patients take “binders” with each meal. These pills are big and numerous, which is why many patients do not take them as told. OLC uses tiny particles of a lanthanum compound to bind more phosphate per pill, so patients would need fewer and smaller tablets.

The company also has UNI-494, an early drug for sudden kidney injury, which has finished a safety study in healthy volunteers.

Is it really new?

Not really. OLC uses the same active idea as Fosrenol, approved in 2004, and took a shorter path to the FDA by relying on that drug’s safety record. What is new is the convenience, and that is a real benefit for patients who already take a dozen or more pills a day.

The competition

The market is crowded and mostly generic. Sevelamer is the cheap standard. Velphoro and Auryxia already offer fewer pills, and Xphozah works in a different way. To win, OLC has to convince dialysis clinics and insurers that a smaller pill is worth paying more for. This is hard for a company with no sales history.

Money

Unicycive held $61.4 million on 30 June 2026 and expects that to last into 2027. Its Q2 net loss of $1.7 million looks small only because of an accounting gain on warrants. By September the factory had been told an inspection was assigned, but it had not yet taken place (BiopharmaWatch).

Risks

• It depends on someone else’s factory. Unicycive cannot control the inspection or its timing.
• Cash. Another long delay would probably mean selling shares at a low price, which dilutes existing holders.
• Commercial challenge. Even with an approval, a small company must fight cheap generics.
• Very small company. Trading volumes are low and the price can swing sharply.

Our take

Unicycive’s problem is frustrating more than scary: nothing is wrong with the drug itself, as far as the FDA has said. But time is money for a company this size, and the shares are close to their 52-week low of about $3.33. The factory inspection is the only news that matters right now. Until it happens, this is a speculative position.